Consistently, analysis of human primary breast cancer database (provided by TCGA Cancer Genomic, Bethesda, MD, USA) indicated that the survival rates of human breast cancer patients with the ERLIN2 gene alteration were significantly lower than those without the ERLIN2 gene alteration (Figure 7f), thus confirming a significant role of ERLIN2 in human breast cancer malignancy. This evidence concerns the gene ERLIN2 and breast cancer.